文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

食管癌治疗的影像学生物标志物。

Imaging biomarkers for the treatment of esophageal cancer.

机构信息

Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 260-8677, Japan.

Department of Surgery, Teikyo University Medical Center, Chiba 299-0111, Japan.

出版信息

World J Gastroenterol. 2019 Jun 28;25(24):3021-3029. doi: 10.3748/wjg.v25.i24.3021.

DOI:10.3748/wjg.v25.i24.3021
PMID:31293338
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6603816/
Abstract

Esophageal cancer is known as one of the malignant cancers with poor prognosis. To improve the outcome, combined multimodality treatment is attempted. On the other hand, advances in genomics and other "omic" technologies are paving way to the patient-oriented treatment called "personalized" or "precision" medicine. Recent advancements of imaging techniques such as functional imaging make it possible to use imaging features as biomarker for diagnosis, treatment response, and prognosis in cancer treatment. In this review, we will discuss how we can use imaging derived tumor features as biomarker for the treatment of esophageal cancer.

摘要

食管癌是预后较差的恶性肿瘤之一。为了改善预后，尝试采用联合多模式治疗。另一方面，基因组学和其他“组学”技术的进步为以患者为中心的治疗方法（称为“个性化”或“精准”医学）铺平了道路。功能成像等影像学技术的最新进展使得将成像特征用作癌症治疗的诊断、治疗反应和预后的生物标志物成为可能。在这篇综述中，我们将讨论如何将成像衍生的肿瘤特征用作食管癌治疗的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8e/6603816/0841159ee1ba/WJG-25-3021-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8e/6603816/dacb1d436f28/WJG-25-3021-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8e/6603816/953bb0608fbe/WJG-25-3021-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8e/6603816/0db78b6109b7/WJG-25-3021-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8e/6603816/0841159ee1ba/WJG-25-3021-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8e/6603816/dacb1d436f28/WJG-25-3021-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8e/6603816/953bb0608fbe/WJG-25-3021-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8e/6603816/0db78b6109b7/WJG-25-3021-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8e/6603816/0841159ee1ba/WJG-25-3021-g004.jpg

相似文献

[1]
Imaging biomarkers for the treatment of esophageal cancer.

World J Gastroenterol. 2019-6-28

[2]
Optimization of b-values in diffusion-weighted imaging for esophageal cancer: Measuring the longitudinal length of gross tumor volume and evaluating chemoradiotherapeutic efficacy.

J Cancer Res Ther. 2017

[3]
Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.

BMC Cancer. 2018-10-20

[4]
Treatment results of neoadjuvant chemoradiotherapy followed by radical esophagectomy in patients with initially inoperable thoracic esophageal cancer.

Jpn J Radiol. 2018-1

[5]
Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.

Gastroenterology. 2017-10-14

[6]
Is the predictive ability of positron emission tomography after neoadjuvant treatment for esophageal cancer ready for prime-time?

Semin Thorac Cardiovasc Surg. 2011

[7]
Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma.

Dis Esophagus. 2011-5-19

[8]
Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade.

Eur J Radiol. 2015-12

[9]
The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012-6

[10]
Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.

J Gastroenterol. 2016-8

引用本文的文献

[1]
Survival outcome prediction of esophageal squamous cell carcinoma patients based on radiomics and mutation signature.

Cancer Imaging. 2025-1-31

[2]
Predefined and data-driven CT radiomics predict recurrence-free and overall survival in patients with pulmonary metastases treated with stereotactic body radiotherapy.

PLoS One. 2024-12-31

[3]
Spectral CT-based nomogram for evaluation of neoadjuvant chemotherapy response in esophageal squamous cell carcinoma.

Eur Radiol. 2024-12-27

[4]
Novel Advances in Qualitative Diagnostic Imaging for Decision Making in Multidisciplinary Treatment for Advanced Esophageal Cancer.

J Clin Med. 2024-1-22

[5]
An artificial neural network-based radiomics model for predicting the radiotherapy response of advanced esophageal squamous cell carcinoma patients: a multicenter study.

Sci Rep. 2023-5-29

[6]
Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers.

Int J Mol Sci. 2023-2-7

[7]
Potential use of high-resolution T2-weighted MRI with histopathologic findings in staging esophageal cancer.

Quant Imaging Med Surg. 2023-1-1

[8]
HOXA10 enhances cell proliferation and suppresses apoptosis in esophageal cancer via activating p38/ERK signaling pathway.

Open Med (Wars). 2022-11-3

[9]
Computed tomography-derived biomarker for predicting the treatment response to neoadjuvant chemoradiotherapy of rectal cancer.

Int J Clin Oncol. 2021-12

[10]
Long noncoding RNA KCNMB2-AS1 promotes the development of esophageal cancer by modulating the miR-3194-3p/PYGL axis.

Bioengineered. 2021-12

本文引用的文献

[1]
DW-MRI for esophageal squamous cell carcinoma, correlations between ADC values with histologic differentiation and VEGF expression: A retrospective study.

Oncol Lett. 2019-3

[2]
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2018-9-12

[3]
Dynamic contrast-enhanced MRI for advanced esophageal cancer response assessment after concurrent chemoradiotherapy.

Diagn Interv Radiol. 2018-7

[4]
Predictive value of diffusion-weighted MR imaging in early response to chemoradiotherapy of esophageal cancer: a meta-analysis.

Dis Esophagus. 2019-4-1

[5]
Prediction of pathologic responders to neoadjuvant chemoradiotherapy by diffusion-weighted magnetic resonance imaging in locally advanced esophageal squamous cell carcinoma: a prospective study.

Dis Esophagus. 2018-2-1

[6]
Heterogeneity of Glucose Metabolism in Esophageal Cancer Measured by Fractal Analysis of Fluorodeoxyglucose Positron Emission Tomography Image: Correlation between Metabolic Heterogeneity and Survival.

Dig Surg. 2017

[7]
The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy.

Radiother Oncol. 2016-11

[8]
Assessment of esophageal carcinoma undergoing concurrent chemoradiotherapy with quantitative dynamic contrast-enhanced magnetic resonance imaging.

Oncol Lett. 2015-12

[9]
Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade.

Eur J Radiol. 2015-12

[10]
Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.

Radiother Oncol. 2015-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索